News & Evens

BiOptic delivers 2021 results ahead of expectations, setting a new record of annual revenue

Investor Relations

Date:

2022 - 01 - 19

The new member of Taiwan's Emerging Stock Boards - BiOptic Inc. (6850) has announced the consolidated revenue of 26.9 million NTD in December 2021, which rewrote a new record high. The 2021 annual consolidated revenue reached 179.28 million, with an annual increase of 45%, which went better than expected. The main reason for the growth is the global sales network are now covering more than 40 countries around the world. In addition, distributors of Illumina, the world's top gene sequencing industry leader, also joined BiOptic Inc. in these couple of years as a distribution partner working together to boost the sales.

Based on capillary gel electrophoresis technology, BiOptic Inc. develops and manufactures Qsep series capillary electrophoresis instruments, consumables, and reagents. The products are sold to more than 50 countries around the world; Qsep series capillary electrophoresis instruments are an open platform for biological fragment analysis, which can be used in biomedical and scientific research fields. It can also cooperate with various detection reagents to develop clinical applications. Compared with other closed detection platforms, it has more flexibility and potential of cooperative development.

Although the global epidemic was severe in 2021, BiOptic Inc. has achieved good sales network of 40 countries and keep developing around the world. New partners joined in 2021 also brings more sales opportunities. BiOptic Inc.'s overall business model is similar to the coordinated sales strategy of printers and ink cartridges. First, the Qsep instrument is deployed globally, and then the subsequent sales of cartridge consumables are stable and can bringing waves of growth momentum.

In recent years, in order to provide low-cost and immediate one-stop-shop style genetic testing solutions, BiOptic Inc. has begun to expand its product chain, by developing multiple genetic testing kits, and provide customers with more practical applications for capillary electrophoresis analysis. In the future, non-invasive oral samples can be used for instant genetic testing in the physical examination center. The cooperation model demonstrates that BiOptic Inc. is committed to provide users with a one-stop-shop solution which is simple and affordable and continues to bring genetic testing into people's daily life with capillary gel electrophoresis technology.

Looking forward to 2022, BiOptic Inc. plans to focus on "development of multi-functional integrated genetic analysis instruments" and "continuous expansion of the application of various tests on BiOptic's open platform” and will continue to expand manpower recruitment and improve production capacity. "Development of functional integrated genetic analysis instrument" allows users to obtain analysis reports in real time through simple operations.